Targeting cancer with Click Chemistry

Less than 2% of administered drugs make it to their desired location in the body. Imagine a world where cancer drugs are activated only where they are needed.
Let's do better 

Latest News

September 11th 2024
event
Shasqi CEO, José Mejía Oneto, speaking on panel at LSX USA World Congress on September 11th, Boston

Shasqi CEO, José Mejía Oneto, MD, PhD, will be participating in a panel discussion "Exploring New Market Trends In Cancer Research and Partnering " at LSX USA World Congress on September 11th in Boston. Joining him will be, Will Ho (IN8Bio), Natalia Ulyanova (Astellas, Elizabeth Wood (Jura Bio) and Tim Sullivan (Spring Discovery)‍. Moderated by Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News.

‍

Read more  ›
September 9th 2024
event
Shasqi speaking at ADC & Radiopharmaceuticals Pharma & Biotech Partner summit
Read more  ›
conference
Shasqi presents Phase 2a results of SQ3370 in STS patients at ASCO 2024
Read more  ›
2024 - ASCO
conference
Shasqi presents Phase 2a results of SQ3370 in STS patients at ASCO 2024

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry in human patients.
Here's how

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.
Antigen-targeted activator
Binds to the tumor
Protodrugs
Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.
A new approach

Changing what's possible

We separate tumor targeting from the payload, and rely on chemistry, not biology, for activation. This  unprecedented flexibility can lead to greater activity and lower toxicity than has been previously possible.

CAPAC has been validated in the clinic and we are rapidly advancing novel therapies for patients with limited effective treatment options.
Our science

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?
Join our team
Interested in exploring a collaboration?
Partner with us
Company
About UsLeadershipOur SciencePartnering
Connect
NewsCareersContact
Policies
Privacy PolicyFCOI Policy